These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 8712214)

  • 1. L-carnitine and erythropoietin requirements in hemodialysis patients.
    Kavadias D; Fourtounas C; Tsouchnikas J; Barboutis K
    Am J Kidney Dis; 1996 Jul; 28(1):156. PubMed ID: 8712214
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease.
    Boran M; Dalva I; Gönenç F; Cetin S
    Nephron; 1996; 73(2):314-5. PubMed ID: 8773364
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of Carnitor for Epogen resistant anemia.
    Simard JC
    ANNA J; 1999 Feb; 26(1):41-2. PubMed ID: 10222857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

  • 5. [Anemia in chronic renal failure. The role of L-carnitine in the treatment of anemia of hemodialyzed patients].
    Wanic-Kossowska M; Kurzawska-Firlej D; Kaźmierski M; Czekalski S
    Pol Arch Med Wewn; 2003 Jan; 109(1):105-11. PubMed ID: 12879773
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis.
    Lilien MR; Duran M; Quak JM; Frankhuisen JJ; Schröder CH
    Pediatr Nephrol; 2000 Nov; 15(1-2):17-20. PubMed ID: 11095004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

  • 8. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels.
    Kooistra MP; Struyvenberg A; van Es A
    Nephron; 1991; 57(1):127-8. PubMed ID: 2046808
    [No Abstract]   [Full Text] [Related]  

  • 9. [Combined therapy with L-carnitine and erythropoietin of anemia in chronic kidney failure patients undergoing hemodialysis].
    Wanic-Kossowska M; Kazmierski M; Pawliczak E; Kobelski M
    Pol Arch Med Wewn; 2007; 117(1-2):14-9. PubMed ID: 17642201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of withdrawing erythropoietin.
    Taylor JE; Henderson IS; Mactier RA; Stewart WK
    BMJ; 1991 Feb; 302(6771):272-3. PubMed ID: 1998794
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 12. The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee.
    Schröder CH;
    Pediatr Nephrol; 2003 Aug; 18(8):805-9. PubMed ID: 12750985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of recombinant erythropoietin in the treatment of anaemia associated with multiple myeloma in a haemodialysis patient.
    Hussein MM; Mooij JM; Roujouleh H
    Nephrol Dial Transplant; 1994; 9(7):876-7. PubMed ID: 7818713
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of renal anemia with recombinant human erythropoietin.
    Schaefer RM; Hörl WH; Massry SG
    Am J Nephrol; 1989; 9(5):353-62. PubMed ID: 2679093
    [No Abstract]   [Full Text] [Related]  

  • 15. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 16. Resistance to erythropoietin: immunohemolytic anemia induced by residual formaldehyde in dialyzers.
    Ng YY; Chow MP; Lyou JY; Hu HY; Yung CH; Fan CD; Huang TP
    Am J Kidney Dis; 1993 Feb; 21(2):213-6. PubMed ID: 8430685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recombinant human erythropoietin and chronic kidney failure: current situation and therapeutic implications].
    Romero González R; Torquet Escuder P
    Med Clin (Barc); 1990 Nov; 95(17):656-9. PubMed ID: 2089205
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of polytransfused hemodialysis patients with recombinant human erythropoietin.
    Bommer J; Huber W; Tewes G; Ritz E; von Wedel S; Küppers S; Weinreich T; Bommer G
    Contrib Nephrol; 1988; 66():131-8. PubMed ID: 3391027
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of erythropoietin on strength and functional status of patients on hemodialysis.
    Guthrie M; Cardenas D; Eschbach JW; Haley NR; Robertson HT; Evans RW
    Clin Nephrol; 1993 Feb; 39(2):97-102. PubMed ID: 8448925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis.
    Salvati F; Strippoli P; Barchetti M; Scatizzi A
    Nephron; 1992; 60(3):371. PubMed ID: 1373475
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.